NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

IQV | NYSE

$260.83 -$8.02 | -2.98%

SIGNAL:

|2026-09-08 |F&G 59 |RSI 48.1

Add to favoritesFavorite

Company Overview:

Market Cap: $42.93B

Trailing PE: 32.4x

FWD PE *: 19.2x

Payout Ratio (TTM): —

52-Week Range: $154.50 - $277.40

* Forward PE is based on street estimates.

10 Year IQV Performance Metrics:

Total Return (with DRIP): 225.2% (12.52% CAGR)

Total Return (no DRIP): 225.2% (12.52% CAGR)

Share Price: 221.8% (12.40% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $32,522

Total Return $ (with DRIP): $22,522

IQV Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

IQV Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

IQV Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

IQV - Revenue

IQV Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%

IQV - Earnings Per Share (EPS)

IQV EPS CAGR:1Y: -0.65%2Y: -11.87%5Y: 11.20%10Y: 7.98%

IQV - Net Income

🔓 See the full chart40% off right now · 7-day free trial

IQV Net Income CAGR:1Y: -3.01%2Y: -15.69%5Y: 8.07%10Y: 11.61%

IQV - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

IQV EBITDA CAGR:1Y: 9.60%2Y: 2.36%5Y: 5.24%10Y: 15.00%

IQV - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

IQV Free Cash Flow CAGR:1Y: 23.29%2Y: -10.06%5Y: -1.79%10Y: 43.92%

IQV - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

IQV Free Cash Flow / Share CAGR:1Y: 26.68%2Y: -6.11%5Y: 0.92%10Y: 39.16%

IQV - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

IQV Operating Income CAGR:1Y: 12.45%2Y: 4.61%5Y: 14.75%10Y: 14.21%

IQV - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

IQV Gross Profit CAGR:1Y: 8.47%2Y: 4.03%5Y: 5.18%10Y: 12.90%

IQV - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

IQV Shares Outstanding CAGR:1Y: -3.41%2Y: -4.72%5Y: -3.01%10Y: 3.25%

IQV - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

IQV Share Buybacks CAGR:1Y: -39.42%2Y: 0.00%5Y: 54.64%10Y: 0.00%

IQV - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

IQV Stock-Based Comp CAGR:1Y: 58.33%2Y: 40.68%5Y: 14.63%10Y: 25.15%

IQV - Expenses

🔓 See the full chart40% off right now · 7-day free trial

IQV Expenses CAGR:1Y: 31.13%2Y: 17.67%5Y: 6.43%10Y: 20.31%

IQV - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

IQV - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

IQV - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

IQV - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

IQV - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

IQV - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

IQV - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

IQV Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%

IQV - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

IQV Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

IQV - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

IQV Actual Revenue CAGR:1Y: 8.74%2Y: 7.02%5Y: 4.90%10Y: 10.90%

IQV - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

IQV Actual EPS CAGR:1Y: -0.65%2Y: -11.87%5Y: 11.20%10Y: 7.98%

IQV - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

IQV Actual Net Income CAGR:1Y: -3.01%2Y: -15.69%5Y: 8.07%10Y: 11.61%

IQV - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

IQV Actual EBITDA CAGR:1Y: 9.60%2Y: 2.36%5Y: 5.24%10Y: 15.00%

Ratios, Profit Margins & Return on Capital:

IQV - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

IQV Net Profit Margin CAGR:1Y: -11.48%2Y: -21.54%5Y: 2.86%10Y: 0.47%

IQV - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

IQV Gross Profit Margin CAGR:1Y: -0.27%2Y: -2.80%5Y: 0.26%10Y: 1.81%

IQV - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

IQV Price to Earnings CAGR:1Y: 23.41%2Y: 9.50%5Y: -13.91%10Y: 3.38%

IQV - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

IQV Price To Sales Ratio CAGR:1Y: 9.74%2Y: -13.83%5Y: -11.34%10Y: 3.94%

IQV - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

IQV Return on Capital Employed CAGR:1Y: -0.03%2Y: -4.42%5Y: 9.93%10Y: -9.31%

IQV - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

IQV Return on Invested Capital CAGR:1Y: -6.88%2Y: -8.15%5Y: 7.31%10Y: -9.87%

Projected Future Returns & Dividends for IQV

Based on past 10-year performance, here are IQV growth metrics:

Share price CAGR of +12.4%
Dividend CAGR of +0%

Using IQV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	IQV (DRIP)	IQV - No DRIP
Current Price	$260.83	$260.83
Start Shares	38.34	38.34
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	38.34	38.34
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$260.83	$260.83
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - IQV

NOTE: Above numbers are our estimate based on IQV's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

IQVIA Holdings Inc. (IQV) had its IPO on 2013-05-09, and is traded on NYSE stock exchange.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

IQV website: https://www.iqvia.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

DCF Model — IQV

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $260.83

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →